Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study.

Journal for Immunotherapy of Cancer
Piotr RutkowskiMario Mandala

Abstract

Obesity is a risk factor for malignancy; however, its prognostic role in patients with metastatic melanoma is controversial. We aim to investigate the prognostic role of body mass index (BMI) in patients with metastatic melanoma receiving mitogen-activated pathway kinase inhibitors (MAPKi), immune checkpoint inhibitors (ICIs) alone or their sequence. Data on patients with metastatic melanoma receiving ≥1 line of systemic treatment were retrieved from prospectively collected databases. Progression-free survival (PFS) and overall survival (OS) were analyzed by means of multivariable stratified Cox regression models; disease control rate (DCR) was analyzed by multivariable stratified logistic regression models. Subgroup analyzes according to the type of treatments received, and in BRAF-mutated patients were pre-planned. All multivariable models included BMI, age, gender, American Joint Committee on Cancer stage, performance status, lactate dehydrogenase and treatment sequencing strategy as covariates. Between November 2010 and November 2018, 688 patients from three Italian and two Polish centers were enrolled. 379 (57%) patients had M1c/d disease, 273 (41%) were female and the mean BMI was 27.1 (SD=4.9). Considering first-line tre...Continue Reading

References

Aug 29, 2009·Cancer Biology & Therapy·Elizabeth L BrandonJohn E Hall
Apr 23, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·F SkowronD Maucort-Boulch
Aug 1, 2016·Current Oncology Reports·Hannah LennonAndrew G Renehan
Jun 7, 2017·Advances in Experimental Medicine and Biology·Atilla Engin
Jul 30, 2019·The Breast : Official Journal of the European Society of Mastology·Grazia VernaciValentina Guarneri

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.